A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults

Jacob P. Lalezari, Edwin DeJesus, Donald W. Northfelt, Gary Richmond, Peter Wolfe, Richard Haubrich, David Henry, William Powderly, Stephen Becker, Melanie Thompson, Fred Valentine, David Wright, Margrit Carlson, Sharon Riddler, Frances F. Haas, Ralph DeMasi, Prakash R. Sista, Miklos Salgo, John Delehanty

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Fingerprint

Dive into the research topics of 'A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science